Therapix is building a specialty pharma­ceu­tical company focused on signif­i­cantly enhancing FDA-approved dronabinol for the treat­ment of Tourette Syndrome and Mild Cognitive Impairment.

Dr. Ascher Shmulewitz, MD, PhD

Interim Chief Executive Officer and Chairman

Chairman of Therapix’s Board of Directors since January 2014, Dr. Shmulewitz has also served as a Board member since February 2013. With doctorate degrees in medicine and engineering, Dr. Shmulewitz spent much of his career as a successful inventor, investor and serial entre­pre­neur in the biomed­ical technolo­gies field, facil­i­tating a wide range of corpo­rate collab­o­ra­tions. He founded and invested in over twenty-four life science compa­nies – many of which enjoyed successful exits via merger & acqui­si­tion trans­ac­tions with large medical device compa­nies – including Arteria Corp., Circulation Inc., Labcoat Medical Ltd., NeoVision Corp, and X‑Cardia Inc. In 1995, Dr. Shmulewitz co-founded San Francisco Science and the Incumed Group which both provide seed funding to promising compa­nies. He also founded the private Israeli invest­ment firm and incubator Medgenesis Partners Ltd. which has invested in over a dozen ventures. Between 1988 and 1992, Dr. Shmulewitz held senior execu­tive positions at Advanced Technology Laboratories Inc.. He received his M.D. from The Technion Medical School, and a Ph.D. in Engineering from Tel Aviv University, Israel.


Chief Technology Officer

Dr. Adi Zuloff-Shani has served as Chief Technologies Officer at Therapix since February 2016, bringing with her more than 15 years of experi­ence as an R&D execu­tive. From 2012 until 2016, Dr. Zuloff–Shani served as a Vice President of Development at Macrocure Ltd. (NASDAQ: “MCUR”) where, aside from leading all research and devel­op­ment activ­i­ties, she inter­acted, and was involved, with the activ­i­ties of all depart­ments including clinical, opera­tions, quality assur­ance, quality control, finance, and regula­tory affairs. Prior to that, Dr. Zuloff-Shani spent eight years as the Senior Scientist in the Research & Development Unit of Magen David Adom’s National Blood Services. Dr. Zuloff-Shani holds a Ph.D. in human biology and immunology from Bar-Ilan University, Israel.


Chief Financial Officer

Mr. Oz Adler has served as our Chief Financial Officer since April, 2018 and as our VP Finance from September, 2017.

Mr. Adler has experi­ence in a wide variety of manage­rial, finan­cial, tax and accounting. Since 2012, Mr. Adler was employed as a certi­fied public accoun­tant at Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global. Mr. Adler holds a B.A. degree in Accounting and Business manage­ment from The College of Management, Israel.